Lv6
1610 积分 2020-10-26 加入
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
2天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
7天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
7天前
已完结
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
1个月前
已完结
Real-world trends in diagnosis, treatment, and survival of non–small cell lung cancer in Vietnam
1个月前
已关闭
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Denatured collagen inhibits neuroblastoma tumor-sphere migration and growth via the LOX/LOXL2 – FAK signaling pathway
2个月前
已完结
Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis
4个月前
已完结
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and high-sales biosimilars
5个月前
已完结
Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050
5个月前
已完结
皖公网安备34019202002308
